Alpha 2.0
Login Register
» Authors » Yankun Liang

Yankun Liang

Explore the profile of Yankun Liang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 1
Followers 0
Related Specialties
Pharmacology
Psychiatry
Psychology
Top 10 Co-Authors
Ling Su
Jingping Zheng
Zhenpo Zhang
Yuting Wang
Lin Ma
Qimin Wu
Chufeng Din
Jiaxin He
Jun Lyu
Haiyan Mai
Published In
Expert Opin Drug Saf
Sci Rep
Endocr Connect
Front Pharmacol
Arch Womens Ment Health
Affiliations
Soon will be listed here.
Recent Articles
1.
Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System
Mai H, Zhang Z, Liang Y, Zheng J, Su L
Ther Adv Drug Saf . 2025 Jan; 16:20420986241311231. PMID: 39758824
Background: Clarithromycin is a widely used antibiotic, but its safety profile, particularly in different age groups, remains inadequately explored. Objectives: This study aims to characterize and illustrate the features of...
2.
Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS)
Zheng J, Zhang Z, Liang Y, Wu Q, Din C, Wang Y, et al.
Arch Womens Ment Health . 2024 Dec; PMID: 39710735
Purpose: This study investigates the potential association between commonly prescribed psychotropic medications, such as Atypical Antipsychotics (AAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), and congenital...
3.
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database
Zheng J, Ma L, Zhang Z, Liang Y, Din C, Wu Q, et al.
Expert Opin Drug Saf . 2024 Dec; 24(2):193-199. PMID: 39668461
Background: Cardiovascular drugs can cross the placenta during pregnancy, potentially exposing the fetus to teratogenic effects. However, ethical constraints on clinical trials with pregnant women limit safety data and result...
4.
Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system
Liang Y, Zhang Z, Zheng J, Wang Y, He J, Zhao J, et al.
Endocr Connect . 2024 Oct; 13(12). PMID: 39404734
Aim: Incretin therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), are crucial for type 2 diabetes treatment. Evidence of their association with gallbladder, biliary diseases, and...
5.
Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
Zhang Z, He J, Liang Y, Wang Y, Zheng J, Ma L, et al.
Expert Opin Drug Saf . 2024 Oct; :1-8. PMID: 39354723
Background: Azithromycin and clarithromycin are commonly used to treat community-acquired pneumonia in adults aged ≥ 65, such as mycoplasma pneumonia. This study aims to evaluate adverse events (AEs) associated with...
6.
Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
Liang Y, Ma L, Wang Y, Zheng J, Su L, Lyu J
Front Pharmacol . 2023 Nov; 14:1253799. PMID: 38026949
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting...
7.
An experimental investigation on the speed of sand flow through a fixed porous bed
Sui W, Liang Y, Zhang X, Jain R, Zhu T
Sci Rep . 2017 Mar; 7(1):54. PMID: 28246393
In this study, we document several experiments that investigate the speed of the flow of fine sand through a fixed porous bed of packed glass beads under various conditions, including...